AZD8931 + Placebo + Paclitaxel
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Conditions
Metastatic, Gastric or Gastro-oesophageal Junction, Cancer
Trial Timeline
Apr 1, 2012 → Mar 1, 2013
NCT ID
NCT01579578About AZD8931 + Placebo + Paclitaxel
AZD8931 + Placebo + Paclitaxel is a phase 2 stage product being developed by AstraZeneca for Metastatic, Gastric or Gastro-oesophageal Junction, Cancer. The current trial status is terminated. This product is registered under clinical trial identifier NCT01579578. Target conditions include Metastatic, Gastric or Gastro-oesophageal Junction, Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic, Gastric or Gastro-oesophageal Junction, Cancer were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01579578 | Phase 2 | Terminated |
Competing Products
20 competing products in Metastatic, Gastric or Gastro-oesophageal Junction, Cancer